BR112018017067A2 - pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1 - Google Patents

pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1

Info

Publication number
BR112018017067A2
BR112018017067A2 BR112018017067A BR112018017067A BR112018017067A2 BR 112018017067 A2 BR112018017067 A2 BR 112018017067A2 BR 112018017067 A BR112018017067 A BR 112018017067A BR 112018017067 A BR112018017067 A BR 112018017067A BR 112018017067 A2 BR112018017067 A2 BR 112018017067A2
Authority
BR
Brazil
Prior art keywords
pyrazolo
pyridines
imidazo
pyridazine
pde1 inhibitors
Prior art date
Application number
BR112018017067A
Other languages
English (en)
Portuguese (pt)
Inventor
Kehler Jan
Juhl Karsten
Kyhn Rasmussen Lars
Marigo Mauro
Jessing Mikkel
Langgård Morten
Jorge Vieira Vital Paulo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112018017067A2 publication Critical patent/BR112018017067A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112018017067A 2016-12-22 2017-12-20 pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1 BR112018017067A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600784 2016-12-22
DKPA201700404 2017-07-06
PCT/EP2017/083721 WO2018115067A1 (en) 2016-12-22 2017-12-20 Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors

Publications (1)

Publication Number Publication Date
BR112018017067A2 true BR112018017067A2 (pt) 2019-07-02

Family

ID=60812077

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018017067A BR112018017067A2 (pt) 2016-12-22 2017-12-20 pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1

Country Status (23)

Country Link
US (2) US10351561B2 (cg-RX-API-DMAC10.html)
EP (1) EP3558988B1 (cg-RX-API-DMAC10.html)
JP (1) JP7074758B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190095301A (cg-RX-API-DMAC10.html)
CN (1) CN110099901B (cg-RX-API-DMAC10.html)
AU (1) AU2017384481A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018017067A2 (cg-RX-API-DMAC10.html)
CA (1) CA3046588A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019001669A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019005538A2 (cg-RX-API-DMAC10.html)
CR (1) CR20190302A (cg-RX-API-DMAC10.html)
DO (1) DOP2019000169A (cg-RX-API-DMAC10.html)
EC (1) ECSP19043790A (cg-RX-API-DMAC10.html)
ES (1) ES2882335T3 (cg-RX-API-DMAC10.html)
IL (1) IL267561A (cg-RX-API-DMAC10.html)
JO (1) JOP20190126A1 (cg-RX-API-DMAC10.html)
MX (1) MX2019007509A (cg-RX-API-DMAC10.html)
PE (1) PE20191323A1 (cg-RX-API-DMAC10.html)
PH (1) PH12019501324A1 (cg-RX-API-DMAC10.html)
RU (1) RU2019116251A (cg-RX-API-DMAC10.html)
TW (1) TW201829405A (cg-RX-API-DMAC10.html)
WO (1) WO2018115067A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201904236B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
RU2020118913A (ru) 2017-12-14 2022-01-14 Х. Лундбекк А/С (H. Lundbeck A/S) Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商H 朗德貝克公司 作為pde1抑制劑之大環
WO2021133915A1 (en) 2019-12-23 2021-07-01 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
CN121159397A (zh) * 2025-09-18 2025-12-19 江西芜锂增致循环科技有限公司 一种应用于高钠锂比卤水中提锂的硝基化β-双酮萃取剂的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
ATE415400T1 (de) 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
BRPI0922700A2 (pt) * 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) * 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
TW201927784A (zh) 2017-12-20 2019-07-16 丹麥商H 朗德貝克公司 作為pde1抑制劑之大環
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors

Also Published As

Publication number Publication date
ES2882335T3 (es) 2021-12-01
JP2020502230A (ja) 2020-01-23
US10351561B2 (en) 2019-07-16
JOP20190126A1 (ar) 2019-05-28
RU2019116251A (ru) 2021-01-22
CN110099901A (zh) 2019-08-06
IL267561A (en) 2019-08-29
US20190352302A1 (en) 2019-11-21
EP3558988A1 (en) 2019-10-30
US20180179200A1 (en) 2018-06-28
ZA201904236B (en) 2020-12-23
CA3046588A1 (en) 2018-06-28
ECSP19043790A (es) 2019-06-30
US10689379B2 (en) 2020-06-23
TW201829405A (zh) 2018-08-16
PH12019501324A1 (en) 2019-09-16
EP3558988B1 (en) 2021-07-07
CR20190302A (es) 2019-08-21
JP7074758B2 (ja) 2022-05-24
PE20191323A1 (es) 2019-09-24
RU2019116251A3 (cg-RX-API-DMAC10.html) 2021-03-31
WO2018115067A1 (en) 2018-06-28
MX2019007509A (es) 2019-09-04
AU2017384481A1 (en) 2019-06-13
KR20190095301A (ko) 2019-08-14
CO2019005538A2 (es) 2019-06-11
CL2019001669A1 (es) 2019-09-06
DOP2019000169A (es) 2019-07-31
CN110099901B (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
CO2019005538A2 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
BR112017026278A2 (pt) 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1
BR112012022650A8 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112018004585A2 (pt) métodos, composições e usos de inibidores da fyn quinase
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
CL2020001550A1 (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
CL2020001548A1 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
BR112017005324A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
BR112016015285A8 (pt) pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
BR112017011335A2 (pt) compostos de 4h-pirido[1,2-a]pirimidin-4-ona
BR112014015192A2 (pt) derivados quinolina como inibidores da enzima pde10a
EA201991062A1 (ru) Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1
EA201892549A1 (ru) ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
BR112017009276A8 (pt) Pirazolo[1,5-a]pirimidinas substituídas e seu uso no tratamento de distúrbios médicos
BR112017023121A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição, método de tratamento do câncer, kit para o tratamento terapêutico do câncer e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements